MedTrace Logo

Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)

NCT00147966 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-03-23

Study results available
· View outcomes & findings →

Summary

Using repeated arthroscopic biopsies of patients with rheumatoid arthritis, the researchers will assess changes in the immune response that occur as a result of treatment with rituximab.

Conditions

Interventions

DRUG

rituximab

treatment with rituximab

Sponsors & Collaborators

Principal Investigators

  • Arthur Kavanaugh, MD · UCSD CIT

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00147966 on ClinicalTrials.gov